文献速递基础与转化研究临床试验与 GCP流行病学与生物统计

MASLD无创检测:LITMUS前瞻性多中心诊断准确性研究

Non-invasive tests in metabolic dysfunction-associated steatotic liver disease: the LITMUS prospective multicentre diagnostic accuracy study.
PubMed 文献 · Lancet · 2026-01-01

LITMUS研究在欧洲和美国13国前瞻性纳入1590例活检确诊MASLD成人,评估12种单标志物和18种多标志物组合对MASH、高危MASH、进展期纤维化和肝硬化的诊断性能。多标志物组合展现潜力,单标志物性能有限。

要点

  • 以GGT为首诊的序贯两步法对进展期纤维化和高危MASH均达到MAC。

核心结论

  • 单标志物检测高危MASH性能有限且不一,多标志物组合潜力大,蛋白组面板表现突出。
  • 研究结果可支持MASLD无创检测策略的选择与实施,并为指南、监管评估和临床试验设计提供依据。

研究设计与样本

  • 前瞻性、多中心诊断准确性研究,在欧洲和美国13个国家招募活检确诊MASLD成人。
  • 共分析1590例有中心判读肝活检且至少一项生物标志物测量的参与者。
  • 评估12种单标志物和18种多标志物组合,参考标准为中心判读的NASH CRN评分系统肝组织学。

主要发现

  • 609例(38%)为活检确诊高危MASH,678例(43%)为MASH,585例(37%)为进展期纤维化,164例(10%)为肝硬化。
  • 以GGT为首诊的序贯两步法对进展期纤维化和高危MASH均达到MAC。

关键数值与推荐

  • 高危MASH定义为MASH合并显著纤维化(纤维化分期F≥2)。
  • MASH定义为NAS≥4且各组分至少1分;进展期纤维化为F≥3;肝硬化为F4。

临床怎么用

  • 在MASLD无创评估中可优先考虑多标志物组合,尤其是蛋白组面板用于高危MASH和进展期纤维化。
  • 以GGT为首诊的序贯两步法可作为达到MAC的检测策略用于进展期纤维化和高危MASH。
  • 单标志物检测高危MASH性能有限,不宜单独用于替代活检。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The advent of regulatory-approved pharmacological treatments for metabolic dysfunction-associated steatotic liver disease (MASLD) calls for precise, non-invasive biomarkers that facilitate early diagnosis, support therapy selection, and aid clinical trial enrolment. The European multicentre LITMUS study aimed to evaluate the diagnostic performance of a broad range of non-invasive biomarkers for identifying patients with metabolic dysfunction-associated steatohepatitis (MASH), at-risk MASH, advanced fibrosis, and cirrhosis. METHODS: In this prospective, multicentre, diagnostic accuracy study, adults with biopsy-confirmed MASLD were prospectively recruited across 13 countries in Europe and the USA. We assessed 12 single markers and 18 multimarker panels. The reference standard was centrally scored liver histology according to the non-alcoholic steatohepatitis Clinical Research Network Scoring System. Target conditions included MASH (Non-Alcoholic Fatty Liver Disease Activity Score ≥4 with ≥1 point per component), at-risk MASH (MASH plus significant fibrosis [fibrosis stage F≥2]), advanced fibrosis (F≥3), and cirrhosis (F4). Performance was evaluated by area-under-the-receiver operating characteristic curve (AUC), with the minimum acceptable criterion (MAC) of AUC higher than 0·80 to indicate potential biopsy replacement. FINDINGS: Between Jan 1, 2018, and June 30, 2023, we analysed data from 1590 participants with centrally scored liver biopsies and at least one biomarker measurement; 609 (38%) had biopsy-confirmed at-risk MASH, 678 (43%) had MASH, 585 (37%) had advanced fibrosis, and 164 (10%) had cirrhosis. For detecting at-risk MASH, SomaSignal showed the highest diagnostic performance (AUC 0·83 [95% CI 0·80-0·85]), significantly exceeding MAC, whereas no other test reached the MAC for MASH only. For advanced fibrosis, SomaSignal showed the highest performance (AUC 0·92 [0·90-0·94]), followed by FibroMeter-VCTE (AUC 0·87 [0·83-0·92]), Agile 3+ and TSP2 (both AUC 0·84 [0·82-0·86]), and NIS4 (0·82 [0·80-0·85]). For cirrhosis, FibroMeter-VCTE showed the highest diagnostic performance (AUC 0·94 [0·90-0·97]) followed by SomaSignal (AUC 0·92 [0·90-0·94]), followed by Agile 3+ (0·88 [0·85-0·91]), Agile 4 (0·87 [0·84-0·90]), ADAPT (0·85 [0·81-0·88]), and ELF, LSM-VCTE, and TSP2 (all 0·84 [0·81-0·87]). Sequential two-step approaches using gamma-glutamyl transferase as a first-line test met the MAC for both advanced fibrosis and at-risk MASH. INTERPRETATION: Although single markers resulted in variable and limited performance when compared to histology for detecting at-risk MASH, multimarker panels showed great potential, with a proteomic panel showing strong diagnostic performance. These findings could support the selection and implementation of non-invasive testing strategies in MASLD and inform future clinical guidelines, regulatory evaluation, and clinical trial design. FUNDING: Innovative Medicines Initiative 2 Joint Undertaking.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Vali Y, Wonders K, Lee J, et al. Non-invasive tests in metabolic dysfunction-associated steatotic liver disease: the LITMUS prospective multicentre diagnostic accuracy study. Lancet. 2026. PMID: 42956772. doi:10.1016/S0140-6736(26)01145-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。